1
|
Ding X, Liu J, Sun Y, Chen X, Zhang X. Jianpi Qingre Tongluo Decoction exerted an anti-inflammatory effect on AS by inhibiting the NONHSAT227927.1/JAK2/STAT3 axis. Heliyon 2024; 10:e34634. [PMID: 39082011 PMCID: PMC11284430 DOI: 10.1016/j.heliyon.2024.e34634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Revised: 07/12/2024] [Accepted: 07/12/2024] [Indexed: 08/02/2024] Open
Abstract
Purpose This study aims to determine whether Jianpi Qingre Tongluo Decoction (JQP) alleviates ankylosing spondylitis (AS) inflammation via the NONHSAT227927.1/JAK2/STAT3 axis. Methods The effect of JQP on immune-inflammatory indicators in AS patients was explored through a combination of data mining, association rule analysis, and random walk model evaluation. Subsequently, network pharmacology and molecular docking were performed to screen out the potential signaling pathway. ELISA, PCR and wb were used to evaluate the effect of JQP on AS-FLS activity and inflammatory factors. The role of NONHSAT227927.1/JAK2/STAT3 combination in inflammation was studied by editing NONHSAT227927.1 and adding the JAK2/STAT3 inhibitor AG490. Involvement of the JAK2/STAT3 pathway was detected by PCR, WB, or immunofluorescence analysis. Results Retrospective data mining results show that JQP can effectively reduce the immune inflammatory response in AS patients. Through network pharmacology and molecular docking, it is speculated that JQP exerts its effect on AS through the JAK2/STAT3 pathway. Overexpression of NONHSAT227927.1 activated the JAK2/STAT3 pathway and promoted the expression of inflammatory factors, while serum containing JQP reversed the effects of NONHSAT227927.1 overexpression. NONHSAT227927.1 silencing inhibits the proliferation of AS-FLSs, inhibits the levels of inflammatory factors, and reduces the expression of JAK2/STAT3 protein. After adding the pathway blocker AG490, it was observed that the cell viability of AS-FLSs was reduced by inflammatory factors and the levels of JAK2/STAT3 were inhibited. , and overexpression of NONHSAT227927.1 can reverse this trend. Conclusions JQP exerted an anti-inflammatory effect on AS by inhibiting the NONHSAT227927.1/JAK2/STAT3 axis.
Collapse
Affiliation(s)
- Xiang Ding
- Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China
- Institute of Rheumatology, Anhui University of Chinese Medicine, Hefei, China
- Anhui University of Traditional Chinese Medicine, Hefei, China
| | - Jian Liu
- Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China
- Institute of Rheumatology, Anhui University of Chinese Medicine, Hefei, China
| | - Yanqiu Sun
- Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China
- Institute of Rheumatology, Anhui University of Chinese Medicine, Hefei, China
- Anhui University of Traditional Chinese Medicine, Hefei, China
| | - Xiaolu Chen
- Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China
- Institute of Rheumatology, Anhui University of Chinese Medicine, Hefei, China
- Anhui University of Traditional Chinese Medicine, Hefei, China
| | - Xianheng Zhang
- Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China
- Institute of Rheumatology, Anhui University of Chinese Medicine, Hefei, China
- Anhui University of Traditional Chinese Medicine, Hefei, China
| |
Collapse
|
2
|
Yi L, Song C, Liu Y, Li D, Xiao T, Guo X, Wu Y. Down-regulation of long noncoding RNA HULC inhibits the inflammatory response in ankylosing spondylitis by reducing miR-556-5p-mediated YAP1 expression. J Orthop Surg Res 2023; 18:551. [PMID: 37525215 PMCID: PMC10388530 DOI: 10.1186/s13018-023-04003-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Accepted: 07/11/2023] [Indexed: 08/02/2023] Open
Abstract
OBJECTIVE Ankylosing spondylitis (AS) is a progressive systemic disease characterized by a chronic inflammatory response in the sacroiliac joints and spine. Long noncoding RNAs suggest significant actions in the progression of AS. Therefore, a specific lncRNA, highly upregulated in liver cancer (HULC), was studied here regarding its functions and related mechanisms in AS. METHODS Measurements of miR-556-5p, HULC, and YAP1 expression were performed on AS cartilage tissues and chondrocytes. The interaction between miR-556-5p and HULC or YAP1 was verified. CCK-8, flow cytometry and enzyme-linked immunosorbent assay were used to evaluate the effects of HULC, miR-556-5p, and YAP1 on the proliferation, apoptosis, and inflammatory response of AS chondrocytes. Furthermore, the action of HULC/miR-556-5p/YAP1 was experimentally observed in AS mice. RESULTS HULC and YAP1 levels were augmented, while miR-556-5p levels were suppressed in AS cartilage tissues and chondrocytes. Downregulating HULC or upregulating miR-556-5p stimulated chondrocyte proliferation and inhibited apoptosis and inflammation in AS. miR-556-5p was a downstream factor of HULC, and YAP1 was a potential target of miR-556-5p. The improvement effect of downregulated HULC on AS chondrocytes was saved when YAP1 expression was forced. In addition, silence of HULC improved the pathological injury of spinal cartilage in AS mice by enhancing miR-556-5p-related regulation of YAP1. CONCLUSION HULC inhibition relieves the inflammatory response in AS by reducing miR-556-5p-mediated YAP1 expression.
Collapse
Affiliation(s)
- LuLu Yi
- Department of Rheumatology, Ganzhou People's Hospital, Ganzhou City, 341000, Jiangxi Province, China
| | - ChangJun Song
- Department of Emergency, Ganzhou People's Hospital, Ganzhou City, 341000, Jiangxi Province, China
| | - YuanYuan Liu
- Department of Obstetrics, Ganzhou People's Hospital, Ganzhou City, 341000, Jiangxi Province, China
| | - DongSheng Li
- Department of Rheumatology, Ganzhou People's Hospital, Ganzhou City, 341000, Jiangxi Province, China
| | - TianTian Xiao
- Department of Rheumatology, Ganzhou People's Hospital, Ganzhou City, 341000, Jiangxi Province, China
| | - XuQin Guo
- Department of Rheumatology, Ganzhou People's Hospital, Ganzhou City, 341000, Jiangxi Province, China
| | - YiCai Wu
- Department of Nephrology, Ganzhou People's Hospital, No. 17, Hongqi Avenue, Zhanggong District, Ganzhou City, 341000, Jiangxi Province, China.
| |
Collapse
|
3
|
Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal 2021; 35:e23964. [PMID: 34418163 PMCID: PMC8418483 DOI: 10.1002/jcla.23964] [Citation(s) in RCA: 48] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 07/08/2021] [Accepted: 08/03/2021] [Indexed: 12/03/2022] Open
Abstract
Background The systemic immune‐inflammation index (SII) is a recently developed indicator for systemic inflammatory response. We aimed to explore the association between SII and disease activity in patients with ankylosing spondylitis (AS). Methods This retrospective study included 136 patients with AS and 63 healthy controls. Patients were divided into two groups according to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI); active group (n = 60) and remission group (n = 76). Clinical, laboratory, and demographic characteristics were recorded. Spearman's correlation analysis was used to determine correlations of SII with C‐reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), and BASDAI in AS patients. Binary logistic regression analysis was used to assess risk factors for AS disease activity. Receiver operating characteristic curve analysis was used to evaluate the diagnostic value of SII and the above variables for the active group compared with the remission group. Results Systemic immune‐inflammation index levels were higher in AS patients than in healthy controls (p < 0.001). SII levels were higher in the active group than in the remission group (p < 0.001). For patients with AS, SII correlated positively with CRP (rs = 0.483, p < 0.001), ESR (rs = 0.374, p < 0.001), and BASDAI (rs = 0.667, p < 0.001). SII (OR = 1.009, 95% CI = 1.006–1.012, p < 0.001) was an independent risk factor affecting AS disease activity. The specificity and sensitivity of SII using a cutoff value of 513.2 were 83.33% and 86.84%, respectively, for the active group. Conclusion Systemic immune‐inflammation index was increased in AS. SII may be a novel indicator for monitoring AS disease activity.
Collapse
Affiliation(s)
| | | | - Kexia Chai
- Department of Rheumatology and Immunology, Qinghai University Affiliated Hospital, Xining, China
| |
Collapse
|
4
|
Wendling D, Prati C, Lequerré T, Miceli C, Dougados M, Molto A, Guillot X. Uveitis occurrence in early inflammatory back pain. Five years data from the prospective French nationwide DESIR cohort. Joint Bone Spine 2020; 88:105100. [PMID: 33166730 DOI: 10.1016/j.jbspin.2020.105100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 10/26/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Uveitis is a frequent extra rheumatological manifestation in axial Spondyloarthritis (SpA). The aim of study was to evaluate the prevalence and incidence of uveitis over the first five years of a prospective nationwide cohort of patients with high suspicion of early axial SpA, and to evaluate its associated factors. METHODS DESIR is a prospective observational cohort of patients with recent onset inflammatory back pain (more than 3 months, less than 3 years), suggestive of axial SpA, All available factors in the database were compared between patients with and without uveitis at 5 years, by uni and then multivariate analysis. Baseline factors associated with new cases of uveitis occurrence over the 5 years were also analyzed. SIGNIFICANCE P less than 0.05. RESULTS After 5 years, 91 patients (out of 480 with complete follow-up) had at least one uveitis episode, giving an estimated prevalence of 18.9% [95% CI: 15.4-22.4]. In multivariate analysis, uveitis was significantly associated with dactylitis, and elevated ESR. New incident uveitis occurred in 31 cases over 5 years, giving an estimated incidence rate of 1.29 [0.84-1.74]/100 patient-years. Incidence of new uveitis was associated in multivariate analysis with baseline factors: diagnosis of SpA, sacro iliac MRI inflammatory SPARCC score, dactylitis, syndesmophyte score. No significant association was found with HLA-B27, DMARDs, BASDAI, ASDAS, BASFI. CONCLUSION Five-years data of the DESIR cohort allowed an estimation of incidence rate of uveitis of 1.3/100p-y; over five years, uveitis was associated with dactylitis, biologic and sacro iliac MRI inflammation.
Collapse
Affiliation(s)
- Daniel Wendling
- Service de Rhumatologie, CHRU de Besançon, Besançon, France; EA 4266, Université de Franche-Comté, Besançon, France.
| | - Clément Prati
- Service de Rhumatologie, CHRU de Besançon, Besançon, France; EA4267, Université de Franche-Comté, Besançon, France
| | - Thierry Lequerré
- Service de Rhumatologie, Normandie Univ, UNIROUEN, Inserm U 1234, CIC-CRB 1404, 76031 Rouen, France; CHU de Rouen, Service de Rhumatologie, 76031 Rouen, France
| | | | | | - Anna Molto
- Rhumatologie, Hôpital Cochin, Paris, France
| | | |
Collapse
|
5
|
Ultra-widefield fundus fluorescein angiography findings in patients with ankylosing spondylitis experiencing uveitis. Int Ophthalmol 2020; 40:2627-2634. [DOI: 10.1007/s10792-020-01443-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 05/23/2020] [Indexed: 11/25/2022]
|
6
|
Zhong H, Zhong M. LINC00311 is overexpressed in ankylosing spondylitis and predict treatment outcomes and recurrence. BMC Musculoskelet Disord 2019; 20:278. [PMID: 31170957 PMCID: PMC6554900 DOI: 10.1186/s12891-019-2647-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 05/20/2019] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND LncRNA LINC00311 participates in osteoporosis, which shows inverse pathological changes to ankylosing spondylitis (AS), indicating that LINC00311 is also involved in AS. METHODS All the participants were enrolled in Ganzhou People's Hospital between January 2016 and January 2018 after this study was approved by Ganzhou People's Hospital Ethics Committee. Disease activity determination, follow-up and RT-qPCR were carried out during the research. RESULTS In the present study we found that LINC00311 was upregulated in AS patients comparing to healthy controls, and upregulation of LINC00311 distinguished AS patients from healthy controls. LINC00311 expression levels were positively correlated with disease activity. Comparing to pre-treatment levels, LINC00311 expression level decreased significantly after treatment. During 2-year follow-up, patients with high levels of LINC00311 showed a significantly higher rate of rehospitalization. CONCLUSIONS Therefore, LINC00311 is overexpressed in AS and predict treatment outcomes and recurrence.
Collapse
Affiliation(s)
- Hongfa Zhong
- Department of orthopaedics, Ganzhou People's Hospital, No.16 Meiguang Avenue, Ganzhou City, Jiang Xi Province, 341000, People's Republic of China
| | - Mingliang Zhong
- Department of orthopaedics, Ganzhou People's Hospital, No.16 Meiguang Avenue, Ganzhou City, Jiang Xi Province, 341000, People's Republic of China.
| |
Collapse
|
7
|
The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. BIOMED RESEARCH INTERNATIONAL 2018; 2018:9460187. [PMID: 30406148 PMCID: PMC6204187 DOI: 10.1155/2018/9460187] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/16/2018] [Revised: 09/05/2018] [Accepted: 09/26/2018] [Indexed: 12/12/2022]
Abstract
Spondyloarthropathies (SpA) encompass a group of chronic inflammatory diseases sharing common genetic and clinical features, including the association with HLA-B27 antigen, the involvement of both the axial and the peripheral skeleton, the presence of dactylitis, enthesitis, and typical extra-articular manifestations such as psoriasis, inflammatory bowel disease, and acute anterior uveitis (AAU). The latter is commonly reported as a noninfectious acute inflammation of the anterior uveal tract and its adjacent structures. AAU may affect more than 20% of SpA patients representing the most common extra-articular manifestation of the disease. Considering the potential consequences of untreated AAU, early diagnosis and aggressive treatment are crucial to avoid complications of remittent or chronic eye inflammation, such as visual loss and blindness. The management of SpA has dramatically improved over the last decades due to the development of new treat-to-target strategies and to the introduction of biologic disease modifying antirheumatic drugs (bDMARDs), particularly tumor necrosis factor alpha inhibitors (TNFis), currently used for the treatment of nonresponder patients to conventional synthetic agents. Along with the improvement of musculoskeletal features of SpA, bDMARDs provided an additional effect also in the management of AAU in those patients who are failures to topical and systemic conventional therapies. Nowadays, five TNFis, one interleukin-17, and one interleukin 12/23 blocker are licensed for the treatment of SpA, with different proven efficacy in preventing and treating ocular involvement. The aim of this review is to summarize the current options and to analyze the future perspectives for the management of SpA-associated AAU.
Collapse
|